tuneTypical Dose
2 mg zeaxanthin + 10 mg lutein daily
Natural Compound
Zeaxanthin
(3R,3'R)-β,β-Carotene-3,3'-diol (Zeaxanthin)
Evidence TierAWADA NOT PROHIBITED
watchEffect Window
3-6 months for meaningful MPOD increase; ongoing protection with continued use.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Zeaxanthin is a carotenoid concentrated in the macula and retina, often paired with lutein. It is used to support visual performance and macular pigment density during aging and high light exposure.
Studies show increased macular pigment density and improvements in glare recovery and contrast sensitivity, especially when combined with lutein. Combination formulas can slow progression of age-related macular degeneration in some high-risk groups. Minority evidence suggests cognitive benefits in older adults due to brain accumulation. Benefits require long-term use and are more apparent with low baseline carotenoid intake.
Xanthophyll carotenoid that accumulates in the macula, filtering blue light and acting as a direct retinal antioxidant.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Slows AMD progression when combined with lutein in AREDS2 formula
Secondary Outcomes
- Increases macular pigment optical density (MPOD)
- Improves contrast sensitivity and glare recovery
Safety
Contraindications and Interactions
Contraindications
- None established
Side effects
- Harmless skin yellowing (carotenodermia) at very high doses
Interactions
- Orlistat/cholestyramine may reduce absorption
- Beta-carotene may compete for absorption
Avoid if
- Smokers taking concurrent high-dose beta-carotene
Evidence
Study-level References
zeaxanthin-SRC-001RCT
Sourceopen_in_newAge-Related Eye Disease Study 2 (AREDS2) Research Group. "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial." JAMA. 2013.
Population: Adults at risk for advanced AMD
Key findings: Lutein/zeaxanthin is a safe and effective replacement for beta-carotene in the AREDS formula; reduced AMD progression in secondary analyses.
Paper content
Lutein/zeaxanthin is a safe and effective replacement for beta-carotene in the AREDS formula; reduced AMD progression in secondary analyses.
zeaxanthin-SRC-002Review
Sourceopen_in_newBernstein PS, et al. "Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease." Prog Retin Eye Res. 2016.
Population: General and at-risk populations for ocular disease
Key findings: Comprehensive evidence supporting macular carotenoid supplementation for MPOD increase and AMD risk reduction.
Paper content
Comprehensive evidence supporting macular carotenoid supplementation for MPOD increase and AMD risk reduction.
zeaxanthin-SRC-003Meta-analysis
Sourceopen_in_newMa L, et al. "Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis." Br J Nutr. 2012.
Population: General population cohorts
Key findings: Higher lutein/zeaxanthin intake is associated with significantly reduced risk of AMD.
Paper content
Higher lutein/zeaxanthin intake is associated with significantly reduced risk of AMD.
zeaxanthin-SRC-004RCT
Sourceopen_in_newStringham JM, Hammond BR. "Macular pigment and visual performance under glare conditions." Optom Vis Sci. 2008.
Population: Healthy adults
Key findings: Supplementation with macular carotenoids improves glare tolerance and visual comfort under bright-light conditions.
Paper content
Supplementation with macular carotenoids improves glare tolerance and visual comfort under bright-light conditions.
zeaxanthin-SRC-005Systematic review and meta-analysis.
Sourceopen_in_newWilson LM, Tharmarajah S, Jia Y, Semba RD, Schaumberg DA, Robinson KA. The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis. Adv Nutr. 2021;12(6):2244-2254. doi:10.1093/advances/nmab071. PMID:34157098.
Population: Adults with healthy eyes across 46 studies.
Dose protocol: Lutein/zeaxanthin at varying doses across 46 studies in healthy-eyed adults.
Key findings: MPOD increased in a dose-dependent manner, with meaningful gains at 5 mg/day or more and the largest increases at 20 mg/day or more.
Notes: Large meta-analysis confirming dose-response for the primary MPOD outcome.
Paper content
This systematic review and meta-analysis pooled 46 studies with 3,189 healthy-eyed adults to quantify the dose-response relationship between lutein/zeaxanthin intake and macular pigment optical density. MPOD increased with dose in a clear gradient. Intakes below 5 mg/day did not significantly change MPOD, while 5 to 20 mg/day produced a modest but significant increase and intakes of 20 mg/day or more produced the largest gains. The findings confirm that supplemental lutein/zeaxanthin reliably builds macular pigment and that higher doses yield greater increases, supporting the AREDS2-range dosing as a minimum effective threshold.
zeaxanthin-SRC-006Double-blind, randomized, placebo-controlled trial.
Sourceopen_in_newStringham NT, Green M, Roche W, Prado-Cabrero A, Mulcahy R, Nolan J. Lutein, zeaxanthin, and meso-zeaxanthin supplementation attenuates inflammatory cytokines and markers of oxidative cardiovascular processes in humans. Nutr Metab Cardiovasc Dis. 2024;34(8):1976-1983. doi:10.1016/j.numecd.2024.05.009. PMID:38890092.
Population: Adult and older adult participants.
Dose protocol: 10 mg lutein + 10 mg meso-zeaxanthin + 2 mg zeaxanthin daily for 6 months.
Key findings: Significant reductions in IL-1 beta, TNF-alpha, and oxidized LDL, suggesting systemic anti-inflammatory and cardiovascular benefits.
Notes: Extends macular carotenoid evidence into cardiovascular biomarker territory.
Paper content
This double-blind RCT tested 6 months of combined lutein (10 mg), meso-zeaxanthin (10 mg), and zeaxanthin (2 mg) supplementation against placebo. The active group showed significant reductions in IL-1 beta, TNF-alpha, and oxidized LDL. The results extend the benefits of macular carotenoids beyond eye health into systemic anti-inflammatory and cardiovascular-protective territory, supporting the hypothesis that these carotenoids reduce oxidative and inflammatory pathways implicated in atherosclerosis.